A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

Official record

Identifier

NCT05538130

Recruiting locations

countries

United StatesAustraliaBrazilCanadaChinaIsraelJapan

Interventions studied

PF-07799544PF-07799933

Lead sponsor

Pfizer

Target enrolment

148 participants

Study type

INTERVENTIONAL

Phase

Phase 1

Status

Active, not recruiting

First posted

Sep 13, 2022

Last updated on the registry

Sep 1, 2026

Age

16 Years

Sex

ALL

Study contact

No public contact is listed on the official record.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Phase 1b Inclusion Criteria:

* Diagnosis of advanced/metastatic solid tumor (excluding colorectal cancer)
* Measurable disease by RECIST version 1.1
* Evidence of a BRAF V600 mutation
* Prior therapy per tumor cohort
* Adequate organ function per protocol

Phase 1b Exclusion Criteria:

* Other active malignancy within 3 years
* Presence of leptomeningeal disease
* History or current evidence of retinal vein occlusion (RVO) or history of retinal degenerative disease
* Concurrent neuromuscular disorder associated with elevated creatine kinase (CK)
* Active gastrointestinal disease as defined per protocol
* History of interstitial lung disease as defined per protocol

Indexed under

Lung Cancer